As
Asklepios Bio
RTP NCFounded 2001200 employees
Private CapbiotechPrivateGenetic Medicine
Platform: Pro10 AAV
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
1
FDA Approved
2
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Voxazumab | ASK-3270 | Phase 1 | 1 | CD38 | SCD | ||
| Zoriosocimab | ASK-116 | Approved | 3 | AHR | MGMDD | ||
| Zanutuximab | ASK-3164 | Phase 2/3 | 2 | USP1 | Asthma | ||
| Pexainavolisib | ASK-1768 | Approved | 3 | SOS1 | GACTCL |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)